Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) Receives Average Rating of “Moderate Buy” from Analysts

Immunocore Holdings PLC Sponsored ADR (NASDAQ:IMCR) has been assigned a consensus rating of “Moderate Buy” from the ten analysts that are presently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, three have given a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year price objective among brokerages that have updated their coverage on the stock in the last year is $57.75.

A number of equities analysts have recently weighed in on the company. Zacks Research upgraded Immunocore from a “strong sell” rating to a “strong-buy” rating in a research note on Thursday, May 7th. Mizuho set a $38.00 target price on Immunocore in a research note on Thursday, February 19th. Needham & Company LLC increased their target price on Immunocore from $71.00 to $75.00 and gave the stock a “buy” rating in a research note on Thursday, February 26th. HC Wainwright reiterated a “buy” rating and set a $100.00 target price on shares of Immunocore in a research note on Monday, April 20th. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Immunocore in a research note on Tuesday, April 21st.

Hedge Funds Weigh In On Immunocore

A number of hedge funds have recently added to or reduced their stakes in the stock. Harbour Investments Inc. increased its stake in Immunocore by 60.2% during the 4th quarter. Harbour Investments Inc. now owns 1,033 shares of the company’s stock worth $36,000 after acquiring an additional 388 shares during the period. DNB Asset Management AS increased its stake in Immunocore by 6.4% during the 3rd quarter. DNB Asset Management AS now owns 8,116 shares of the company’s stock worth $295,000 after acquiring an additional 488 shares during the period. Mirae Asset Global Investments Co. Ltd. increased its stake in Immunocore by 37.0% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,120 shares of the company’s stock worth $74,000 after acquiring an additional 572 shares during the period. R Squared Ltd increased its stake in Immunocore by 7.4% during the 4th quarter. R Squared Ltd now owns 8,849 shares of the company’s stock worth $307,000 after acquiring an additional 606 shares during the period. Finally, Leonteq Securities AG bought a new position in Immunocore during the 4th quarter worth $30,000. Institutional investors own 84.50% of the company’s stock.

Immunocore Stock Performance

IMCR opened at $28.93 on Wednesday. The stock has a market cap of $1.47 billion, a price-to-earnings ratio of -52.60 and a beta of 0.74. The company has a quick ratio of 4.15, a current ratio of 4.18 and a debt-to-equity ratio of 1.00. Immunocore has a 12-month low of $27.56 and a 12-month high of $40.71. The business has a 50 day moving average of $30.29 and a 200-day moving average of $33.08.

Immunocore (NASDAQ:IMCR) last announced its earnings results on Wednesday, May 6th. The company reported $0.25 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.51. The company had revenue of $106.68 million for the quarter, compared to analyst estimates of $145.20 million. Immunocore had a negative return on equity of 7.07% and a negative net margin of 6.68%.The firm’s quarterly revenue was up 13.6% compared to the same quarter last year. During the same quarter last year, the company earned $0.10 earnings per share. On average, equities research analysts expect that Immunocore will post -0.16 earnings per share for the current year.

About Immunocore

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.